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Multicomponent therapies, originating through deliberate mixing of
drugs in a clinical setting, through happenstance, and through ratio-
nal design, have a successful history in a number of areas of medicine,
including cancer, infectious diseases, and CNS disorders. We have
developed a high-throughput screening method for identifying ef-
fective combinations of therapeutic compounds. We report here that
systematic screening of combinations of small molecules reveals
unexpected interactions between compounds, presumably due to
interactions between the pathways on which they act. Through
systematic screening of 120,000 different two-component combi-
nations of reference-listed drugs, we identified potential multicom-
ponent therapeutics, including (i) fungistatic and analgesic agents
that together generate fungicidal activity in drug-resistant Candida
albicans, yet do not significantly affect human cells, (ii) glucocorticoid
and antiplatelet agents that together suppress the production of
tumor necrosis factor- in human primary peripheral blood mononu-
clear cells, and (iii) antipsychotic and antiprotozoal agents that do not
exhibit significant antitumor activity alone, yet together prevent the
growth of tumors in mice. Systematic combination screening may
ultimately be useful for exploring the connectivity of biological
pathways and, when performed with reference-listed drugs, may
result in the discovery of new combination drug regimens.
Modern biological research and much of drug discovery is oftendriven by the search for new molecularly targeted therapeu-
tics (1–3). In this approach, a specific protein is studied in vitro, in
cells and in whole organisms, and evaluated as a drug target for a
specific therapeutic indication (3, 4). The refinement of this ap-
proach has resulted in the ability to discover compounds with great
selectivity for a chosen protein target. The recent success of Gleevec
(imatinib mesylate), an inhibitor of the breakpoint cluster region-
abelson (BCR-ABL) kinase, and of selective cyclooxygenase-2
(COX-2) inhibitors Vioxx (rofecoxib) and Celebrex (celecoxib) are
evidence that the target-based approach can be successful (5, 6).
Systems biology, however, has revealed that human cells and
tissues are composed of complex, networked systems with redun-
dant, convergent and divergent signaling pathways (7–10). For
example, the redundant function of proteins involved in cell-cycle
regulation (11) has inspired efforts to intervene simultaneously at
multiple points in these signaling pathways (12). A drug discovery
approach consonant with this systems biology framework, and
complementary to the target-based approach, entails identification
of combinations of small molecules that perturb cellular signaling
networks in a desired fashion.
Recognition of the potential for multipoint intervention in
biology and medicine has a long history. As early as 1928, Loewe
(13) observed and quantified effects of combinations of compounds
that were different from, and not predicted by, the activities of the
constituents. The concepts of synergy, additivism, and antagonism
have been explored extensively, particularly in the fields of phar-
macology and toxicology (14–17). Moreover, patients with infec-
tious diseases and with cancer have benefited from combination
chemotherapy, where combination drugs are in many cases the
standard of care (18, 19). This clinical experience has led to the
testing of combinations of drugs in patients as an explicit strategy
for drug improvement by physicians (18, 20). However, this clinical
mixing, and its in vitro surrogate, has generally been conducted with
agents already known to be effective in the therapeutic area of
interest, or where there is a clear rationale for the combination.
Such limited combination testing samples only a tiny fraction of
combination space and is unlikely to have resulted in the selection
of optimal combinations among the very large number of possibil-
ities. A comparatively small number of compounds will provide a
very large number of combinations; a collection of 1,000 com-
pounds yields 500,000 pairwise combinations, and many more
higher-order combinations. Moreover, variations in molar ratio and
timing of compound addition can be relevant and increase the size
of the search space. Therefore, whereas combinatorial diversity is
valuable in that it allows for the simultaneous use of multiple probe
molecules, an efficient screening method is needed. We report
herein the development and application of such a method.
Methods
Combination High-Throughput Screening (cHTS) Procedure. Com-
pounds were stored as dry powders at the temperature specified by
the supplier. Before screening, compounds were weighed into
polypropylene vials and dissolved in DMSO when possible, and into
distilled, deionized water when necessary. Compound solutions
were transferred into polypropylene 384-well master plates con-
taining an appropriate volume of diluent (generally DMSO) by
using a Perkin–Elmer Life Sciences (Boston) Multiprobe. Com-
pounds were then serially diluted left to right, or top to bottom by
using a Perkin–Elmer MiniTrak. Compounds were transferred to a
dilution daughter plate and mixed to create a diluted compound
stock in the appropriate assay buffer. All dilution and assay plates
[Nunc (Rochester, NY) polystyrene, untreated or tissue-culture
treated, as required] were filled by using an Apogent (Hudson, NH)
PlateMate 384-well pipettor. Aliquots from two or more compound
dilution plates were then dispensed to the final combination assay
plate by using custom protocols driving a MiniTrak. Cells were
added to the assay plate postcompound addition by using a Thermo
Labsystems Multidrop (Ventraa, Finland) in a biosafety cabinet.
Cells and compounds were then incubated at the temperature and
CO2 concentration specified for each assay. Postincubation pro-
cessing of the assay plates included direct readout of cell number
by using a BMG (Offenberg, Germany) NEPHELOstar and the
addition of a detection reagent and further incubation before
fluorescence detection by using a Wallac (Gaithersburg, MD)
Victor V plate reader. In the case of immunoinflammatory
screening, assay plates were spun and supernatants transferred
to a protein-binding plate for incubation before ELISA process-
ing and detection of time-resolved fluorescence by using a Victor
V plate reader.
Candida albicans Proliferation Assay. In these experiments, ampho-
tericin B (Sigma) was used as a positive control for antifungal
activity. Stock solutions of each compound were prepared and
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stored at 20°C. Before use, stock solutions were diluted into
growth medium to produce 10 solutions. A clinical isolate (strain
17) of fluconazole-resistant C. albicans was seeded in 384-well
plates at a density of 1,000 cells per ml in growth medium (RPMI
medium 1640; 2% glucose without bicarbonate or phenol red,
buffered with 0.165 M Mops to pH 7.0) with 11% Alamar blue
(BioSource International, Camarillo, CA) at 35°C for 16 h. Com-
pounds were tested in a 36-point dose matrix by using a six-point,
4-fold dilution series centered on the empirically derived concen-
tration required for 50% effect (EC50) for each compound in this
assay. Alamar blue, which is metabolically reduced by mitochondria
to produce a fluorescent dye, was quantified fluorometrically by
using a Fusion plate reader (Packard) to determine the percentage
of viable cells remaining. Fluconazole (Interchem, Paramus, NJ)
and phenazopyridine (Sigma) were additionally tested at the indi-
cated concentrations for their effect on the proliferation of flucon-
azole-resistant C. albicans (strain 17; Seattle Biomedical Research
Institute, Seattle). Results are the average of three measurements.
Colony-Forming Unit (cfu) Assay. Fungicidal activity was measured
with a cfu assay. Fluconazole-sensitive C. albicans was seeded at a
starting density of 500 cfuml in 10 ml of RPMI medium 1640
supplemented with 2% glucose. Cultures were treated as indicated
above and grown for 24 h at 32°C with shaking at 250 rpm and the
absorbance of each culture was measured. To remove drugs, the
cultures were spun down and resuspended in medium lacking drugs.
One thousand yeast-sized particles were then plated on sabouraud
agar plates with no supplementary compounds and incubated
overnight at 32°C. The number of colonies was counted in each
case.
Dye Efflux Assay. Fluconazole-resistant C. albicans cultures were
pretreated with compound(s) for 30 min at 32°C and then treated
with the fluorescent dye rhodamine G for 1 h at 32°C to allow
loading of the dye into cells. Cultures were spun down and
resuspended in medium alone to remove both unloaded dye and the
test compound(s). Cells were allowed to recover without com-
pound(s) present for 2 h at 32°C (resulting in dye efflux in untreated
cells) and then diluted into ice-cold PBS to stop dye efflux. Cells
were spun down again and resuspended in ice-cold PBS for
microscopic analysis. Fluorescence, indicating a loss of dye efflux
capability remaining in cells, was detected by using an inverted
fluorescence compound microscope (Nikon TS100-F) fitted with a
tetramethylrhodamine B isothiocyanate (TRITC) filter set. Images
were collected by using a cooled charge-coupled device camera
(Spot; Diagnostic Instruments, Sterling Heights, MI) with a fixed
set of acquisition parameters.
Tumor Necrosis Factor  (TNF-) and IFN- ELISAs. Primary human
white blood cells (purified from whole blood supplied by the Rhode
Island Blood Center, Providence, RI) were stimulated with phorbol
12-myristate 13-acetate (PMA) (Sigma) and ionomycin (Sigma)
and simultaneously treated with the indicated concentrations of
dexamethasone andor dipyridamole for 18 h. Supernatants were
removed and subjected to an ELISA to determine the percent
inhibition of cytokine production.
A549 Tumor Cell in Vitro BrdUrd Incorporation Assay. Cell cultures
composed of A549 nonsmall cell lung carcinoma cells (21) were
treated with the indicated concentrations of chlorpromazine and
pentamidine for 90 h and viability was measured by BrdUrd
incorporation.
A549 Tumor Cell in Vivo Mouse Xenograft Assay. A549 lung carci-
noma cells were injected into severe combined immunodeficient
(SCID) mice and allowed to form a tumor with an average volume
of 400 mm3. Mice were treated over 14 days with saline alone, 20
mgkg paclitaxel alone (Monday, Wednesday, and Friday), 20
mgkg pentamidine alone (daily), 5 mgkg chlorpromazine alone
(daily), or 20 mgkg pentamidine and 5 mgkg chlorpromazine
(daily). After treatment was discontinued, the mice were monitored
until the tumors in the saline-treated mice reached 1,000 mm3 in
size.
Results
cHTS. To perform the large number of requisite experiments for
combinatorial screening, and because no adequate commercial
system exists, we have designed and implemented a custom robotic
screening and informatics system. This technology, which we refer
to as cHTS, can be applied to two-component or higher-order
screening, and incorporates both an efficient experimental strategy
and analytic methods to determine whether a beneficial combina-
tion interaction occurs between compounds.
Our systematic testing of all pairwise combinations for a com-
pound set begins by defining the activity of each compound as a
single agent in the assay system, and then by testing in two groups
(active agents and inactive agents) all pairwise combinations of
these compounds. Separating the testing of active and inactive
compounds makes an efficient and complete search of all pairwise
combinations tractable, when combined with an automated robotic
screening and informatics system. Inactive compounds, showing no
detectable activity as single agents are tested in pools initially (four
compounds per pool) and active pools are then deconvoluted to
identify the specific pairwise combination with activity of interest.
Because these compounds are inactive on their own and because we
have observed that active combinations comprising two inactive
compounds are infrequent, we can take advantage of the higher
efficiency allowed by pooling, without the confusion generated by
overlapping activities. Compounds that show detectable activity on
their own (active compounds) are more difficult to assess in pools
at a single concentration and are best tested at a range of concen-
trations to identify potency shifts as well as increases in intrinsic
activity. We test each active compound against all other compounds
(both active and inactive) in dose matrices comprising six concen-
trations (including zero) for each compound. Thus, our standard
screening matrix for active single agents takes place in 36 different
wells of a microtiter plate.
We have implemented a number of algorithms for quantifying
synergy in our screening experiments. For example, median effect
and isobolographic analyses effectively identify combinations in
which one drug enhances the potency of the other drug, but these
models are not appropriate for combinations in which one drug
enhances only the intrinsic activity of the other (15–17, 22, 23).
Clinically and mechanistically useful combination interactions may
occur through either a shift in potency or an increase in intrinsic
activity. Moreover, additivism and synergy can both be useful
therapeutically, and are readily distinguished from the vast majority
of random combinations that are neither synergistic nor additive.
We employ three standard reference models of additivism to
identify synergies. The highest single agent (HSA) model is the
larger of the effects produced by each of the combination’s single
agents at the same concentrations as in the mixture. In contrast, the
Bliss additivism model (23) predicts the combined response C for
two single compounds with effects A and B is
C  A  B  AB,
where each effect is expressed as fractional inhibition between 0
and 1. These effect-based synergy models make no assumptions
about the functional form of the dose-response curves, and do not
require dose-response information that lies outside the range
sampled by each screening matrix. The third model, Loewe addi-
tivity (13), measured by the combination index (15), is dose-based,
and applies only to activity levels achieved by the single agents.
Compound combinations that show excess inhibition at a chosen
significance level over a synergy model are selected for followup.
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Such candidates are confirmed by using repeat assays on 384-well
plates at higher density concentration coverage, and by using other
in vitro and in vivo assays.
Inhibiting Growth of Fluconazole-Resistant C. albicans. The identifi-
cation of azole-enhancing agents and pathways is important for the
treatment of fungal infections caused by C. albicans, in part because
resistance to fluconazole and crossresistance with triazole antifun-
gal drugs represents a growing clinical problem (24). We applied
our cHTS method to screen all pairwise combinations of 30
compounds that inhibit C. albicans proliferation. In the first stage
of this experiment, we empirically identified 30 reference-listed
drugs (Fig. 1A) with moderate to high activity in a C. albicans
antifungal assay by using the viability dye Alamar blue, which is
reduced by mitochondrial reductases in live fungal cells. These 30
compounds were identified by testing 500 reference-listed drugs
at 4gml for their effect on the viability of proliferating C. albicans
in 384-well plates (data not shown). Of these 30 drugs, 9 are
currently used as antifungal agents and 21 are used for other
indications (Fig. 1A).
All 435 possible two-component combinations of these 30 active
compounds were tested in duplicate in 36-point dose matrices (six
doses for each compound, representing 31,320 data points) for their
effects on the proliferation of fluconazole-resistant C. albicans (e.g.,
Fig. 1B). The five test concentrations for each compound were
chosen by first determining the EC50 of each compound as a single
agent in this assay, and then selecting 4-fold and 16-fold higher and
lower concentrations. Each combination was then scored to identify
fungistatic or fungicidal effects that were greater than the effects of
the individual components by using an Alamar blue proliferation
assay. For each combination, we calculated the difference between
the observed effect of each combination of doses and the predicted
effect based on the three models of additivism described above (Fig.
1 C and D).
This combination screen of active compounds produced 22
pairwise combinations that showed an effect in excess of the HSA
model, each for a specific range of compound concentrations,
giving an overall HSA hit rate of 5%. Of the confirmed active
pools, none comprised two known antifungal agents, six comprised
antifungal and nonantifungal agents, and 16 comprised two non-
antifungal agents (Fig. 1).
Fig. 1. Multicomponent therapeutics that prevent proliferation of fluconazole-resistant C. albicans. All 435 possible two-component combinations of 30 compounds
were tested in duplicate in 36-point dose matrices to identify synergistic combinations. C. albicans cells were treated with compounds in 384-well plates and the extent
of inhibition of Alamar blue fluorescence was determined. (A) Overview of synergistic combinations in C. albicans Alamar blue proliferation assay. Yellow columns and
rows indicate compounds that are commonly used as antifungal agents. Purple squares indicate combinations for which neither compound is used as an antifungal
agent on its own and red indicates combinations for which one, but not both, of the compounds is used as an antifungal agent on its own. (B) A sample combination
dose matrix, showing the combined effect of pentamidine and phenazopyridine at six concentrations (including a zero concentration point) each. The experimentally
measured inhibition of Alamar blue signal is shown for each pair of combinations. The color of the squares also indicates the level of Alamar blue inhibition. (C) The
calculated excess inhibition over the predicted Bliss additivism model. The predicted Bliss additive effect (see text) was subtracted from the experimentally observed
inhibition at each pair of concentrations. (D) The calculated excess inhibition over the HSA.









Enhancing the Activity of Fluconazole in Fluconazole-Resistant C.
albicans. In a related screen, we sought to identify reference-listed
compounds that could enhance the activity of fluconazole in
fluconazole-resistant C. albicans. By using a similar experimental
procedure to that used for the active compound screen (vide supra),
we tested fluconazole in combination with 560 compounds, all in
36-point dose matrices, irrespective of their single-agent antifungal
activity. This screen produced 20 confirmed pairwise combinations
with combined activity in excess of the HSA model that were
nonobvious (i.e., the second compound was not a known antifungal
compound).
A notable example that emerged from this screen is the combi-
nation of fluconazole and phenazopyridine (PAP), which is a
urinary tract analgesic (25). This combination of compounds syn-
ergistically inhibited the proliferation of otherwise fluconazole-
resistant C. albicans (Fig. 2 A–C). The antifungal activity of PAP
alone, which is modest, has not, to our knowledge, been previously
reported. The combination of fluconazole and PAP was more
effective than either compound alone (Fig. 2D). Moreover, a cfu
assay determined that whereas fluconazole alone is fungistatic, the
combination of PAP and fluconazole is fungicidal (Fig. 2E). The
combination of fluconazole and PAP did not significantly affect
the proliferation of primary human lung fibroblasts, A549 lung
carcinoma cells, or mouse skin fibroblasts (data not shown), indi-
cating that the combination is selective for C. albicans relative to
mammalian cells.
To test the possibility that this combination inhibits fungal cells’
ability to eliminate fluconazole through multidrug resistance
pumps or Candida drug resistance pumps, we performed dye efflux
experiments. Fluconazole-resistant C. albicans cultures were pre-
treated with compound(s), treated with the dye rhodamine G,
washed, and allowed to recover without compound(s) present. The
ability of compound(s) to prevent rhodamine G efflux was deter-
mined by measuring the remaining fluorescence in fungal cells.
Whereas fluconazole or PAP alone had little effect on dye efflux,
the combination efficiently prevented dye efflux (Fig. 2F). This
result demonstrates that the two compounds together affect mem-
brane pump activity, either directly, or indirectly by disrupting
mitochondrial ATP synthesis, even though neither agent on its own
has such an effect.
Cytokine Modulation in Primary Human Blood Cells. As part of our
program to identify anti-inflammatory combination drugs that
make use of multipoint intervention mechanisms, we created a
phenotypic assay system that examines both intercellular and
intracellular signaling networks and adapted this assay to cHTS. In
the primary screen, we monitored the production of the immuno-
stimulatory cytokine TNF- in primary human blood cells in
response to various methods of stimulation, including stimulation
with lipopolysaccharide (LPS), and with PMA and ionomycin.
By using the described cHTS method (vide supra), we tested
20,000 combinations from a set of 600 approved drugs. Twenty-six
of the most interesting combinations were confirmed by using
higher-density 100-point dose matrices. One of the interesting
combination effects we discovered was that the antiplatelet agent
dipyridamole, when used in conjunction with the glucocorticoid
dexamethasone, effectively prevents TNF- production in response
to PMAionomycin stimulation (Fig. 3 A and B). The TNF--
suppressive activity of steroids is well documented (26–28) and it
has been noted that dipyridamole exhibits TNF- suppressive
effects, possibly through potentiation of adenosine-mediated action
at the adenosine A2a receptor (29–32). However, their combined
action in vitro has not been described, nor would knowledge of their
proposed modes of action have predicted that in combination they
would yield the observed interaction effect (Fig. 3 A and B). In fact,
many other combinations of singly active TNF--suppressing com-
pounds were tested and few exhibited the steroid-sparing profile of
dipyridamole (data not shown).
An important feature of dipyridamole’s action is that it enhances
the glucocorticoid-mediated inhibition of TNF-, but not of all
cytokines (such as IFN- or IL-2; Fig. 3 C and D), nor does it
significantly reduce cell viability (data not shown). Moreover,
combinations of steroids alone do not result in TNF- inhibition
beyond a plateau of maximal effect (Fig. 3E), illustrating that some
compounds are limited by a maximum achievable inhibition. A
combination that increases TNF- inhibition beyond the maximum
level achieved by a glucocorticoid may be mechanistically and
therapeutically valuable.
Inhibiting Proliferation of Cancer Cells. To determine whether mul-
ticomponent therapeutics discovered in vitro through cHTS could
Fig. 2. The combination of fluconazole and phenazopyridine selectively inhib-
its proliferation of fluconazole-resistant C. albicans. (A) The percent inhibition of
fluconazole-resistant C. albicans proliferation is shown for the indicated concen-
trations of fluconazole and phenazopyridine, determined by using an Alamar
blue proliferation assay. The average of three measurements is shown. (B) The
calculated excess inhibition over the Bliss additivism model. The predicted Bliss
additive effect (see text) was subtracted from the experimentally observed inhi-
bition at each pair of concentrations. (C) The calculated excess inhibition over
the HSA. (D) Percent inhibition of fluconazole-resistant C. albicans proliferation
at concentrations showing optimal synergy [250 M fluconazole (flu) andor 20
M phenazolepyridine (PAP)]. (E) Fungicidal activity, determined by using a cfu
assay. Fluconazole-resistant C. albicans were treated with 20M PAP andor 250
M flu, or 4 M amphotericin B (amp B) as a fungicidal positive control, and in
each case an equal number of yeast particles were plated in the absence of any
compound. The number of colonies that grew after each treatment regime is
indicated. (F) The combination of PAP and flu prevents dye efflux. Fluconazole-
resistant C. albicans cells were treated with 20 M PAP andor 250 M flu and
the effect on efflux of rhodamine G was determined by using fluorescence
microscopy. Phase-contrast images of the yeast cells are shown in each case to
confirm that a large number of cells were present in each case, but that dye efflux
was only effectively inhibited when both PAP and flu were present. For all
numerical figures shown, the average of three measurements is represented.
Error bars, 1 SD.
7980  www.pnas.orgcgidoi10.1073pnas.1337088100 Borisy et al.
be effective in vivo, we first performed an antiproliferative screen
to identify compound combinations that selectively kill, or prevent
the proliferation, of human tumor cells in vitro. Using our cHTS
method (vide supra), we tested 100,000 combinations from a set of
600 approved drugs. We identified and confirmed 13 synergistic
combinations, after eliminating 28 synergistic combinations in
which both compounds were known antineoplastics drugs.
One of these combinations, comprising the antipsychotic agent
chlorpromazine and the antiprotozoal agent pentamidine, was
selected for further testing in vivo. Both of these compounds have
moderate antiproliferative activities on their own in vitro in A549
lung carcinoma cells (Fig. 4 A–C), but neither demonstrates sub-
stantial activity at concentrations that would be considered clini-
cally relevant in vitro or in vivo, and neither is currently used as an
anticancer drug (Fig. 4 A–C). In combination, however, these
compounds prevented the growth of A549 lung carcinoma cells in
vitro (Fig. 4 A–C) and in vivo in a human tumor xenograft assay in
mice (Fig. 4D). The combination was even more effective than
paclitaxel, a clinically used anticancer drug, at concentrations of the
two drugs that correspond to clinically achievable plasma concen-
trations (Fig. 4D). This growth inhibition occurred without loss of
body weight or other visible behavior changes characteristic of mice
treated with standard chemotherapeutic drugs (data not shown).
Additional in vitro testing in a normal lung fibroblast cell line (Fig.
4E) has demonstrated that this combination exhibits greater anti-
proliferative activity in A549 tumor cells than in cells derived from
normal lung tissue. Together, these data indicate that the combi-
nation may possess a therapeutically useful tumor-selective activity.
We sought to determine whether any of the previously described
mechanisms and targets for pentamidine or chlorpromazine were
relevant to the activity of this combination in the A549 proliferation
assay. For chlorpromazine, the primary mechanism of action is
dopamine receptor antagonism, but other ascribed mechanisms
include -adrenergic receptor antagonism, histamine receptor an-
tagonism, and calmodulin inhibition (33, 34). Our experiments
(data not shown) confirmed the previously reported observation
that at high concentrations, the phenothiazines (including chlor-
promazine) have antiproliferative activity as single agents, and that
they can enhance certain existing chemotherapeutic agents, includ-
Fig. 3. Corticosteroids combined with dipyridamole (DP) selectively inhibit
cytokine production. (A) Percent inhibition of TNF- production in stimulated
human peripheral blood cells (average of two measurements) using dexameth-
asone and dipyridamole at the indicated concentrations. (B) Excess inhibition
over HSA for dipyridamole and dexamethasone. (C and D) Dipyridamole and
dexamethasone inhibit production of TNF- (C), but not IFN- (D). As a compar-
ison, two steroids, fludrocortisone and prednisolone (E), were tested in combi-
nation for their effect on TNF- production. In each case, the dilution factor is
calculated based on the highest concentration tested [3 M DP, 0.25 M dexa-
methasone, 1M fludrocortisone (FLU), and 1M prednisolone (PRED)] for each
agent, selected based on the empirically determined dose curves.
Fig. 4. Chlorpromazine, an antipsychotic agent, and pentamidine, an antipro-
tozoal agent, together selectively prevent tumor cell growth in vitro and in vivo.
(A) Percent inhibition of A549 proliferation, measured by using a BrdUrd incor-
poration assay (average of two measurements). (B and C) Excess antiproliferative
activity over the Bliss additivism model (B) and the HSA (C). The predicted Bliss
additive (B) or HSA (C) level of inhibition was subtracted from the level observed
in A and plotted to indicate concentration regimes in which synergy is observed.
(D) Effect of chlorpromazine and pentamidine on the growth of A549 lung
carcinoma cell tumors in SCID mice. Tumor size as a function of time is plotted for
each cohort and is treated as indicated. (E) The antiproliferative effect of the
combination of chlorpromazine (chlor) and pentamidine (pent) was measured in
humanlungcarcinomacells (A549; ref.21), incoloncarcinomacells (HCT116),and
in normal human lung fibroblasts by using Alamar blue (46) to illustrate that
higher concentrations are required for inhibition of normal fibroblasts relative to
carcinoma cells.









ing radiomimetic drugs (35–40). However, as described below, the
mechanism by which chlorpromazine acts to enhance pentamidine
in A549 cells is distinct from its reported behavior with bleomycin,
consistent with the idea that understanding the actions of single
compounds is insufficient to predict fully their behavior in combi-
nation. Compounds that antagonize calmodulin (calmidazolium
chloride and pimozide, but not trifluoperazine) mimic the effect of
chlorpromazine in terms of single-agent activity and cooperativity
with pentamidine in our assay system (data not shown). In contrast,
compounds that antagonize dopamine receptors (pergolide, SKF-
83566, and risperidone), adrenergic receptors (atenolol, dihydro-
ergotamine, and imipramine) or histamine receptors (cimetidine,
diphenhydramine, meclizine, and loratadine) had no activity as
single agents or in combination with pentamidine in our assay
system, suggesting that these receptors play no role in the antipro-
liferative activity of chlorpromazine.
For pentamidine, previously described mechanisms include
DNA binding and consequent inhibition of DNA synthesis (41, 42),
modulation of polyamine levels (43), and calmodulin antagonism
(44). Whereas pentamidine is known to possess DNA minor
groove-binding activity (42, 45), our studies indicate that it does not
behave as a classical DNA-damaging agent in this A549 prolifera-
tion assay, nor simply as an inhibitor of DNA repair. To ascertain
whether these known mechanisms are relevant to the ability of
pentamidine to inhibit tumor cell proliferation in combination with
chlorpromazine, we tested the effects of other compounds that
operate by each of these mechanisms on tumor cell proliferation in
the presence and absence of chlorpromazine (data not shown).
DNA-binding agents (DAPI and WP631, but not netropsin) were
active as single agents and cooperated with chlorpromazine in our
assay system. Calmodulin inhibitors (calmidazolium chloride, pimo-
zide, and trifluoperazine) were also active as single agents and
cooperated with chlorpromazine in our assay system. Somewhat
surprisingly, a modulator of polyamine levels (N,N-diethylsper-
mine) cooperated with both pentamidine and chlorpromazine in
our assay system.
From these results we conclude that (i) DNA binding and
inhibition of calmodulin have individual and cooperative antipro-
liferative effects in A549 cells, (ii) dopamine, histamine, and
adrenergic receptor antagonism do not have antiproliferative ef-
fects in A549 cells, and (iii) the mechanism underlying the anti-
proliferative effect of the combination of chlorpromazine and
pentamidine is likely to involve in part, calmodulin inhibition,
DNA binding, modulation of polyamine levels, and possibly other
mechanisms.
Discussion
Using our cHTS technology to screen two-component combina-
tions of reference-listed drugs in cell-based assays relevant to
disease, we observed unexpected synergistic interactions that may
be attributable to the interconnected signaling networks existing
within and between cells. Our screening approach is complemen-
tary to other methods for exploring systems biology and protein
networks and may be useful for determining connections between
pathways that are functionally important. Because reference-listed
drugs are well studied in terms of their molecular mechanisms and
targets, these compounds may aid in understanding the underlying
biological pathways that may be affected by combination treat-
ment. The combinations identified may also serve as multicom-
ponent drugs that are appropriate for advancement to clinical
development.
In some instances, a synergistic combination that we, to our
knowledge, discovered empirically will have relevant citations in the
literature such that it may appear to have been almost predictable
with hindsight. However, many other equivalent predictions would
also be made from the literature and these usually do not result in
synergy when tested experimentally. In this sense, biological liter-
ature contains many anticipatory observations and speculations
regarding connections between pathways (and compounds), most
of which do not ultimately prove to be synergistic when tested
directly.
This approach might be expanded beyond small molecules to
other methods of perturbation such as cDNA overexpression or
RNA interference-based messenger RNA knockdown. Such sys-
tematic combination perturbations may ultimately help define the
interactions among human genes and proteins, and the reagents
that act on them, that elicit nonlinear and nonadditive phenotypic
outcomes. A practical application of this cHTS methodology is the
creation of combination drugs through systematic screening of
compounds in disease-relevant phenotypic assays. Mining the com-
binatorics of multicomponent effects promises to result in rapid
production of medicines and will define an approach to the
systematic discovery of therapeutic agents.
We thank Joshua Lederberg and Jacob Goldfield for valuable advice.
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